Biostem outlines $10M-$12M annual cash opex cuts as it targets in-house manufacturing in H1 2027Nov 12, 7:27 PM ET#BSEM
BioStem Technologies’ CEO and COO invest $1M in cash through exercise of stock optionsOct 8, 7:29 AM ET#BSEM